Multimodal Oncological Therapy Comprising Stents, Brachytherapy and Regional Chemotherapy for Cholangiocarcinoma

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	ANDRAŠINA Tomáš VÁLEK Vlastimil PÁNEK Jiří KALA Zdeněk KISS Igor TUČEK Štěpán ŠLAMPA Pavel
Rok publikování	2010
Druh	Článek v odborném periodiku
Časopis / Zdroj	Gut and Liver
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.5009/gnl.2010.4.S1.S82
Obor	Ostatní lékařské obory
Klíčová slova	Cholangiocarcinoma; Brachytherapy; Infusions; Intra-arterial; Stents
Popis	BACKGROUND/AIMS: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months . The median overall survival times were 25.2 months and 11.5 months in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively.CONCLUSIONS: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency.